Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).

##STR00001##

Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).

##STR00001##

The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). ##STR00001##

The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

Compounds of Formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and are as defined in the description.

Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.

Compounds of Formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and are as defined in the description.

Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.

Provided is a tetrahydronaphthalene derivative that can be used as an LAT1-selective inhibitor and an LAT1-selective substrate. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), M represents S, O, NH or the like; R.sup.1C represents any one structure selected from the group consisting of a 5- to 7-membered aromatic heterocyclic group having a substituent, a C5- to 7-membered aromatic cyclic group having a substituent and a substituted or unsubstituted 8- to 16-membered polycyclic group, or the like; and n represents an integer of 0 to 5. The present invention also relates to a composition for treating cancer, a medicine for BNCT, a diagnostic drug for cancer, an LAT1-selective inhibitor, or a composition for enhancing a BNCT effect, each containing the compound or the pharmaceutically acceptable salt thereof.

##STR00001##

Provided is a tetrahydronaphthalene derivative that can be used as an LAT1-selective inhibitor and an LAT1-selective substrate. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), M represents S, O, NH or the like; R.sup.1C represents any one structure selected from the group consisting of a 5- to 7-membered aromatic heterocyclic group having a substituent, a C5- to 7-membered aromatic cyclic group having a substituent and a substituted or unsubstituted 8- to 16-membered polycyclic group, or the like; and n represents an integer of 0 to 5. The present invention also relates to a composition for treating cancer, a medicine for BNCT, a diagnostic drug for cancer, an LAT1-selective inhibitor, or a composition for enhancing a BNCT effect, each containing the compound or the pharmaceutically acceptable salt thereof.

##STR00001##